OncoResponse has secured USD 40 million in second-round financing to develop drugs based on antibodies taken from cancer survivors. The cash will be designated to get five programs from antibody-mining R&D of OncoResponse that is presently concentrated on melanoma, non-small cell lung cancer, prostate cancer, gastric cancer and chronic myeloid leukemia, into human testing. The company bagged USD 9.5 million in its series A round in 2015.
Kodiak Sciences gets ready for USD 100 Million IPO to progress Age-related Macular Degeneration (AMD) drug
Kodiak Sciences, California-based company, has filed to set up USD100 million in its IPO that will bolster the phase 2 development of anti-VEGF drug for eye diseases. It is now being tried in multiple trials in age-related macular degeneration (AMD) and diabetic retinopathy. The treatment is injected squarely into the eyes. The company is targeting to progress this with its prime drug, KSI-301.
Biodesy contemplates USD 20 Million in VC funding
The molecule-monitoring company, Biodesy declared that it has brought in USD 20 million in venture capital and chosen a new CEO. The company has been developing high-throughput systems that identify structural shifts in proteins and other biological molecules in real time, gauging how shape changes can affect function, pathway regulation and responses to drugs and novel candidates.
